Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid vs alendronate in postmenopausal osteopenia/osteoporosis
2006-001703-11Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in osteopenia and osteoporosis comparing Zoledronic acid (Aclasta) with Alendronate (Alendrom-Hexal) (2 arms). Primary endpoint: Serum NTx AUC over 12 months. Started Aug 2006; status: completed.
02
Drugs
zoledronic acidalendronate
03
Conditions
osteopeniaosteoporosis
Beyond the preview
Go deeper on 2006-001703-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001703-11.